A Very Rare Cause of Markedly Elevated CA 19-9: Glucagon-like Peptide-1 Receptor Agonists.
CA 19-9 明顯升高的非常罕見原因:胰高血糖素樣肽-1 受體激動劑。
Diabetes Metab 2024-09-13
這個案例顯示了胰高血糖素樣肽-1 (GLP-1) 受體激動劑的罕見副作用,通常用於治療第二型糖尿病。患者的腫瘤標記碳水化合物抗原19-9 (CA 19-9) 水平顯著上升,但並未發現腫瘤。研究發現停用GLP-1後,CA 19-9水準恢復正常,顯示這類藥物可能會影響腫瘤標記,強調在治療過程中需密切監測這些指標,並根據患者的具體情況調整糖尿病管理。
PubMedDOI♡
站上相關主題文章列表
Multifocal C-cell Hyperplasia and Marked Hypercalcitoninemia in a Diabetic Patient Treated With Glucagon-Like Peptide-1 Agonist With Concurrent Multinodular Goiter and Hyperparathyroidism.
一位糖尿病患者接受胰高血糖素樣肽-1激動劑治療,伴隨多發性C細胞增生、明顯高鈣化甲狀腺素血症、並發生多結節性甲狀腺腫和甲狀旁腺功能亢進。
Cureus 2023-02-09
Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy.
葡萄糖樣肽-1 受體激動劑治療與食道胃十二指腸鏡檢查中的胃殘留物之關聯。
J Diabetes Investig 2023-05-25
Atypical Presentation of a Preexisting Pancreatic Pseudocyst with Glucagon-Like Peptide-1 Agonist as a Possible Trigger for Exacerbation: A Case Report.
胰臟偽囊的非典型表現:一例可能由類胰高血糖素-1激動劑觸發惡化的病例報告。
Cureus 2023-12-01
Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes.
二型糖尿病患者中胰臟癌風險與葡萄糖樣肽-1受體激動劑的關聯。
JAMA Netw Open 2024-01-08
Glucagon-Like Peptide-1 Receptor Agonists Increase Solid Gastric Residue Rates on Upper Endoscopy Especially in Patients With Complicated Diabetes: A Case-Control Study.
葡萄糖樣肽-1 受體激動劑增加上消化道內視鏡檢查中的固體胃殘留率,尤其在合併糖尿病併發症的患者中:一項病例對照研究。
Am J Gastroenterol 2024-05-01
Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis.
甲狀腺增生和腫瘤:與食品藥物管理局不良事件報告系統中的葡萄糖樣肽-1 受體激動劑相關的不良事件:回顧性分析。
JMIRx Med 2024-05-13
Suppressed thyroid stimulating hormone levels after initiation of a subcutaneous glucagon-like peptide-1 receptor agonist in a post-thyroidectomy patient managed with levothyroxine case report.
甲狀腺切除後接受皮下胰高血糖素樣肽-1受體激動劑治療的患者,在服用左旋甲狀腺素後甲狀腺刺激素水平抑制的個案報告。
J Am Pharm Assoc (2003) 2024-07-11
Problematic Pharmacokinetics: A Case of Recurrent Pancreatitis Post Discontinuation of a Glucagon-Like Peptide 1 Receptor Agonists.
問題藥物動力學:停用 Glucagon-Like Peptide 1 受體激動劑後反覆發作的胰臟炎案例。
J Pharm Pract 2024-08-07